论文部分内容阅读
本文讨论了30例多发性骨髓瘤的临床表现、分期及化疗方法对本病预后的影响。30例中做免疫学分型者23例,其中IgG 型10例,平均生存期22个月,IgA 型3例,IgD+BJ型3例,平均生存期11个月,BJ 型6例,平均生存期仅4.7个月,不产生型1例,生存期长达66个月。骨损严重程度、体内瘤细胞总量及肾功损害与预后关系密切,骨髓内瘤细胞%对生存期有一定影响,但非绝对相关。本组27例化疗结果表明短程间歇的CONP 联合化疗是一可取的治疗方案,生存期可达3～4年。
This article discusses the clinical manifestations of 30 patients with multiple myeloma, staging and chemotherapy on the prognosis of the disease. Of 30 cases, 23 cases were immunostained, of which 10 cases had IgG type. The average survival time was 22 months. IgA type 3 cases and IgD + BJ type 3 cases. The average survival time was 11 months. There were 6 cases of BJ type with average survival Only 4.7 months, no cases of type 1, survival of up to 66 months. The severity of bone loss, the total number of tumor cells in vivo and renal damage and prognosis are closely related to the survival of bone marrow tumor cells have a certain impact, but not absolutely relevant. The group of 27 chemotherapy results show that short-term intermittent CONP combined with chemotherapy is a desirable treatment, the survival period of up to 3 to 4 years.